Rini BI, Plimack ER, Stus V et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1116–1127. https://doi.org/10.1056/NEJMoa1816714

Article  CAS  PubMed  Google Scholar 

Motzer R, Alekseev B, Rha SY et al (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384:1289–1300. https://doi.org/10.1056/NEJMoa2035716

Article  CAS  PubMed  Google Scholar 

Lee DW, Gardner R, Porter DL et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124:188–195. https://doi.org/10.1182/blood-2014-05-552729

Article  CAS  PubMed  PubMed Central  Google Scholar 

National Cancer Institute. Common Terminology Criteria for Adverse Events v.5.0 and v.6.0 (CTCAE). Available at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50

Thompson JA, Schneider BJ, Brahmer J et al (2022) Management of immunotherapy-related toxicities, version 1.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20:387–405. https://doi.org/10.6004/jnccn.2022.0020

Article  CAS  PubMed  Google Scholar 

Heng DYC, Xie W, Regan MM et al (2013) External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 14:141–148. https://doi.org/10.1016/S1470-2045(12)70559-4

Article  PubMed  PubMed Central  Google Scholar 

Shimabukuro-Vornhagen A, Gödel P, Subklewe M et al (2018) Cytokine release syndrome. J Immunother Cancer 6:56. https://doi.org/10.1186/s40425-018-0343-9

Article  PubMed  PubMed Central  Google Scholar 

Ahamadi M, Freshwater T, Prohn M et al (2017) Model-based characterization of the pharmacokinetics of pembrolizumab: a humanized anti-PD-1 monoclonal antibody in advanced solid tumors. CPT Pharmacometrics Syst Pharmacol 6:49–57. https://doi.org/10.1002/psp4.12139

Article  CAS  PubMed  Google Scholar 

Rassy EE, Assi T, Rizkallah J et al (2017) Diffuse edema suggestive of cytokine release syndrome in a metastatic lung carcinoma patient treated with pembrolizumab. Immunotherapy 9:309–311. https://doi.org/10.2217/imt-2016-0134

Article  CAS  PubMed  Google Scholar 

Rotz SJ, Leino D, Szabo S et al (2017) Severe cytokine release syndrome in a patient receiving PD-1-directed therapy. Pediatr Blood Cancer. https://doi.org/10.1002/pbc.26642

Article  PubMed  Google Scholar 

Zhao L, Yang Y, Li W et al (2018) Nivolumab-induced cytokine-release syndrome in relapsed/refractory Hodgkin’s lymphoma: a case report and literature review. Immunotherapy 10:913–917. https://doi.org/10.2217/imt-2018-0025

Article  CAS  PubMed  Google Scholar 

Honjo O, Kubo T, Sugaya F et al (2019) Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report. J Immunother Cancer 7:97. https://doi.org/10.1186/s40425-019-0582-4

Article  PubMed  PubMed Central  Google Scholar 

Oda H, Ishihara M, Miyahara Y et al (2019) First case of cytokine release syndrome after nivolumab for gastric cancer. Case Rep Oncol 12:147–156. https://doi.org/10.1159/000496933

Article  CAS  PubMed  PubMed Central  Google Scholar 

Normand CV, Zender HO, Staehli DM et al (2021) Acute cytokine release syndrome after a first dose of pembrolizumab as second-line treatment for metastatic, programmed death-ligand 1-positive, non-small-cell lung cancer. J Oncol Pharm Pract 27:1528–1533. https://doi.org/10.1177/1078155220980813

Article  CAS  PubMed  Google Scholar 

Amlani A, Barber C, Fifi-Mah A et al (2020) Successful treatment of cytokine release syndrome with IL-6 blockade in a patient transitioning from immune-checkpoint to MEK/BRAF inhibition: a case report and review of literature. Oncologist 25:e1120–e1123. https://doi.org/10.1634/theoncologist.2020-0194

Article  PubMed  PubMed Central  Google Scholar 

Ohira J, Kawamoto M, Sugino Y et al (2020) A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors. Medicine 99:e19741. https://doi.org/10.1097/MD.0000000000019741

Article  PubMed  PubMed Central  Google Scholar 

Sackstein P, Zaemes J, Kim C (2021) Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report. J Immunother Cancer 9(7):e002855. https://doi.org/10.1136/jitc-2021-002855

Article  PubMed  PubMed Central  Google Scholar 

Tay SH, Toh MMX, Thian YL et al (2022) Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: a case series of 25 patients and review of the literature. Front Immunol 13:807050. https://doi.org/10.3389/fimmu.2022.807050

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee DW, Kochenderfer JN, Stetler-Stevenson M et al (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385:517–528. https://doi.org/10.1016/S0140-6736(14)61403-3

Article  CAS  PubMed  Google Scholar 

Gardner RA, Finney O, Annesley C et al (2017) Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129:3322–3331. https://doi.org/10.1182/blood-2017-02-769208

Article  CAS  PubMed  PubMed Central  Google Scholar 

Osa A, Uenami T, Koyama S et al (2018) Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight 3:e59125. https://doi.org/10.1172/jci.insight.59125

Article  PubMed  PubMed Central  Google Scholar 

Owen CN, Bai X, Quah T et al (2021) Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Ann Oncol 32:917–925. https://doi.org/10.1016/j.annonc.2021.03.204

Article  CAS  PubMed  Google Scholar